WO2010054138A3 - Modulators of atp-binding cassette transporters - Google Patents
Modulators of atp-binding cassette transporters Download PDFInfo
- Publication number
- WO2010054138A3 WO2010054138A3 PCT/US2009/063475 US2009063475W WO2010054138A3 WO 2010054138 A3 WO2010054138 A3 WO 2010054138A3 US 2009063475 W US2009063475 W US 2009063475W WO 2010054138 A3 WO2010054138 A3 WO 2010054138A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- atp
- modulators
- binding cassette
- present
- cassette transporters
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA201106976A UA110192C2 (en) | 2008-11-06 | 2009-06-11 | Modulators of atp-binding cassette transporter |
AU2009313409A AU2009313409A1 (en) | 2008-11-06 | 2009-11-06 | Modulators of ATP-Binding cassette transporters |
RU2011122646/04A RU2011122646A (en) | 2008-11-06 | 2009-11-06 | ATP-BINDING CASSETTE CARRIER MODULATORS |
EP09795592A EP2362874A2 (en) | 2008-11-06 | 2009-11-06 | Modulators of atp-binding cassette transporters |
JP2011535676A JP2012508246A (en) | 2008-11-06 | 2009-11-06 | Modulator of ATP-binding cassette transporter |
CA2742980A CA2742980A1 (en) | 2008-11-06 | 2009-11-06 | Modulators of atp-binding cassette transporters |
CN2009801539702A CN102272128A (en) | 2008-11-06 | 2009-11-06 | Modulators of atp-binding cassette transporters |
NZ592693A NZ592693A (en) | 2008-11-06 | 2009-11-06 | Modulators of ATP-binding cassette (ABC) transporters including cystic fibrosis transmembrane conductance regulator (CFTR) |
MX2011004834A MX2011004834A (en) | 2008-11-06 | 2009-11-06 | Modulators of atp-binding cassette transporters. |
BRPI0921234A BRPI0921234B8 (en) | 2008-11-06 | 2009-11-06 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS INCLUDING SUCH COMPOUNDS, IN VITRO USE AND USE OF SUCH COMPOUNDS AND KIT FOR USE IN MEASURING THE ACTIVITY OF AN ABC TRANSPORTER OR A FRAGMENT THEREOF IN AN IN VITRO OR IN VIVO BIOLOGICAL SAMPLE INCLUDING SUCH COMPOUNDS |
IL212727A IL212727A (en) | 2008-11-06 | 2011-05-05 | Modulators of atp-binding cassette transporters, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases |
ZA2011/03856A ZA201103856B (en) | 2008-11-06 | 2011-05-25 | Modulators of atp-binding cassette transporters |
IL233996A IL233996A (en) | 2008-11-06 | 2014-08-07 | Use of modulators of atp-binding cassette transporters for the manufacture of medicaments for treating male infertility or pancreatic insufficiency |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11215208P | 2008-11-06 | 2008-11-06 | |
US61/112,152 | 2008-11-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010054138A2 WO2010054138A2 (en) | 2010-05-14 |
WO2010054138A3 true WO2010054138A3 (en) | 2010-11-11 |
Family
ID=42153560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/063475 WO2010054138A2 (en) | 2008-11-06 | 2009-11-06 | Modulators of atp-binding cassette transporters |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP2362874A2 (en) |
JP (2) | JP2012508246A (en) |
KR (1) | KR20110089170A (en) |
CN (2) | CN105693701B (en) |
AU (1) | AU2009313409A1 (en) |
BR (1) | BRPI0921234B8 (en) |
CA (2) | CA2948104C (en) |
CL (1) | CL2011001004A1 (en) |
HK (1) | HK1226076A1 (en) |
IL (2) | IL212727A (en) |
MX (1) | MX2011004834A (en) |
NZ (2) | NZ592693A (en) |
RU (2) | RU2011122646A (en) |
SG (1) | SG10201501168RA (en) |
UA (2) | UA104876C2 (en) |
WO (1) | WO2010054138A2 (en) |
ZA (1) | ZA201103856B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8952050B2 (en) | 2006-04-07 | 2015-02-10 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
LT2489659T (en) | 2004-06-24 | 2018-03-26 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
HUE032640T2 (en) | 2005-11-08 | 2017-10-30 | Vertex Pharma | Heterocyclic modulators of ATP-binding cassette transporters |
RS60205B1 (en) | 2005-12-28 | 2020-06-30 | Vertex Pharma | Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
HUE055205T2 (en) | 2006-04-07 | 2021-11-29 | Vertex Pharma | Preparation of modulators of atp-binding cassette transporters |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US8969386B2 (en) | 2007-05-09 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
CN101910134B (en) | 2007-12-07 | 2014-03-19 | 沃泰克斯药物股份有限公司 | Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids |
US8507534B2 (en) | 2007-12-07 | 2013-08-13 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
CN103382201B (en) | 2008-02-28 | 2016-12-28 | 沃泰克斯药物股份有限公司 | Heteroaryl derivative as CFTR regulator |
EP2940016A1 (en) * | 2008-11-06 | 2015-11-04 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
UA104876C2 (en) * | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Modulators of atp-binding cassette transporters |
LT2821400T (en) | 2009-03-20 | 2018-02-12 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
RU2711481C2 (en) * | 2010-03-25 | 2020-01-17 | Вертекс Фармасьютикалз Инкорпорейтед | Solid forms of (r)-1-(2, 2-difluorobenzo[d][1, 3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
JP2013523833A (en) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 3- (6- (1- (2,2-difluorobenzo [D] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid pharmaceutical composition and Its administration |
CA2796646A1 (en) * | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
EP2560650A1 (en) * | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
CA2797118C (en) | 2010-04-22 | 2021-03-30 | Vertex Pharmaceuticals Incorporated | Process of producing cycloalkylcarboxamido-indole compounds |
CA2796642A1 (en) * | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
US20120046330A1 (en) | 2010-08-23 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d] [1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
AR085509A1 (en) | 2011-03-09 | 2013-10-09 | Bayer Cropscience Ag | INDOL- AND BENCIMIDAZOLCARBOXAMIDS AS INSECTICIDES AND ACARICIDES |
CN109966264A (en) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | Pharmaceutical composition and its application |
EP2872122A1 (en) | 2012-07-16 | 2015-05-20 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
TWI692469B (en) | 2012-11-09 | 2020-05-01 | 南韓商Lg化學股份有限公司 | Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient |
ITMI20122065A1 (en) | 2012-12-03 | 2014-06-04 | Univ Padova | USE OF CFTR CORRECTORS IN THE TREATMENT OF STRUCTURAL MUSCLE PATHOLOGIES |
US9944700B2 (en) | 2013-03-13 | 2018-04-17 | Novartis Ag | Notch2 binding molecules for treating respiratory diseases |
WO2015073231A1 (en) | 2013-11-12 | 2015-05-21 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
EP2878339A1 (en) | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
AR099336A1 (en) | 2014-02-17 | 2016-07-13 | Bayer Cropscience Ag | INDOL- AND BENCIMIDAZOLCARBOXAMIDS AS INSECTICIDES AND ACARICIDES |
KR102447581B1 (en) | 2014-04-15 | 2022-09-28 | 버텍스 파마슈티칼스 인코포레이티드 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
EP2932966A1 (en) | 2014-04-16 | 2015-10-21 | Novartis AG | Gamma secretase inhibitors for treating respiratory diseases |
PL3203840T3 (en) | 2014-10-06 | 2021-01-11 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
KR20170063954A (en) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
SI3221692T1 (en) | 2014-11-18 | 2021-11-30 | Vertex Pharmaceuticals Inc. | Process of conducting high throughput testing high performance liquid chromatography |
BR112017014213A2 (en) | 2014-12-31 | 2018-04-10 | Auspex Pharmaceuticals Inc | cystic fibrosis transmembrane conductance regulator cyclopropanecarboxamide modulators. |
GB201504878D0 (en) | 2015-03-23 | 2015-05-06 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
WO2016160945A1 (en) | 2015-03-31 | 2016-10-06 | Concert Pharmaceuticals, Inc. | Deuterated vx-661 |
GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
WO2017180794A1 (en) | 2016-04-13 | 2017-10-19 | Skyline Antiinfectives, Inc. | Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams |
WO2018064632A1 (en) | 2016-09-30 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
WO2018107100A1 (en) * | 2016-12-09 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
BR112019025801A2 (en) | 2017-06-08 | 2020-07-07 | Vertex Pharmaceuticals Incorporated | treatment methods for cystic fibrosis |
AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2019028228A1 (en) | 2017-08-02 | 2019-02-07 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
AU2018380426B2 (en) | 2017-12-08 | 2023-05-18 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
TWI810243B (en) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | Pharmaceutical compositions for treating cystic fibrosis |
PT3752510T (en) | 2018-02-15 | 2023-03-15 | Vertex Pharma | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
CN109651160B (en) * | 2019-01-25 | 2021-08-13 | 上海应用技术大学 | Method for preparing enamine compound by catalyzing phenylacetylene hydroamination reaction |
CN111763198B (en) * | 2019-04-01 | 2021-09-07 | 新发药业有限公司 | Preparation method of 5-substituted cyclopropyl formylaminoindole derivative |
TW202120517A (en) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | Process of making cftr modulators |
WO2021030552A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
TW202115092A (en) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | Modulators of cystic fibrosis transmembrane conductance regulator |
CN112624956A (en) * | 2019-10-08 | 2021-04-09 | 兰州大学 | Novel process for preparing 3-indolesulfonic acid derivatives |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004035571A1 (en) * | 2002-10-15 | 2004-04-29 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
WO2007117715A2 (en) * | 2006-04-07 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
EP1664006A2 (en) * | 2003-09-06 | 2006-06-07 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
LT2489659T (en) | 2004-06-24 | 2018-03-26 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
UA104876C2 (en) * | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Modulators of atp-binding cassette transporters |
EP2940016A1 (en) * | 2008-11-06 | 2015-11-04 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
WO2011050325A1 (en) * | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
-
2008
- 2008-11-12 UA UAA201106975A patent/UA104876C2/en unknown
-
2009
- 2009-06-11 UA UAA201106976A patent/UA110192C2/en unknown
- 2009-11-06 SG SG10201501168RA patent/SG10201501168RA/en unknown
- 2009-11-06 EP EP09795592A patent/EP2362874A2/en not_active Withdrawn
- 2009-11-06 BR BRPI0921234A patent/BRPI0921234B8/en active IP Right Grant
- 2009-11-06 JP JP2011535676A patent/JP2012508246A/en not_active Withdrawn
- 2009-11-06 CN CN201610012624.4A patent/CN105693701B/en active Active
- 2009-11-06 WO PCT/US2009/063475 patent/WO2010054138A2/en active Application Filing
- 2009-11-06 NZ NZ592693A patent/NZ592693A/en not_active IP Right Cessation
- 2009-11-06 KR KR1020117012767A patent/KR20110089170A/en not_active Application Discontinuation
- 2009-11-06 NZ NZ610972A patent/NZ610972A/en not_active IP Right Cessation
- 2009-11-06 AU AU2009313409A patent/AU2009313409A1/en not_active Abandoned
- 2009-11-06 CA CA2948104A patent/CA2948104C/en active Active
- 2009-11-06 RU RU2011122646/04A patent/RU2011122646A/en not_active Application Discontinuation
- 2009-11-06 CN CN2009801539702A patent/CN102272128A/en active Pending
- 2009-11-06 CA CA2742980A patent/CA2742980A1/en not_active Abandoned
- 2009-11-06 MX MX2011004834A patent/MX2011004834A/en active IP Right Grant
-
2011
- 2011-05-05 CL CL2011001004A patent/CL2011001004A1/en unknown
- 2011-05-05 IL IL212727A patent/IL212727A/en active IP Right Grant
- 2011-05-25 ZA ZA2011/03856A patent/ZA201103856B/en unknown
-
2012
- 2012-06-01 HK HK16114548A patent/HK1226076A1/en unknown
-
2014
- 2014-08-07 IL IL233996A patent/IL233996A/en active IP Right Grant
- 2014-09-30 RU RU2014139599A patent/RU2014139599A/en not_active Application Discontinuation
- 2014-11-25 JP JP2014237756A patent/JP2015061860A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004035571A1 (en) * | 2002-10-15 | 2004-04-29 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
WO2007117715A2 (en) * | 2006-04-07 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8952050B2 (en) | 2006-04-07 | 2015-02-10 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US8952049B2 (en) | 2006-04-07 | 2015-02-10 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
Also Published As
Publication number | Publication date |
---|---|
MX2011004834A (en) | 2011-07-28 |
EP2362874A2 (en) | 2011-09-07 |
JP2015061860A (en) | 2015-04-02 |
IL233996A (en) | 2015-09-24 |
BRPI0921234B1 (en) | 2021-06-22 |
CA2742980A1 (en) | 2010-05-14 |
CL2011001004A1 (en) | 2012-03-16 |
CN102272128A (en) | 2011-12-07 |
RU2011122646A (en) | 2012-12-20 |
NZ592693A (en) | 2013-05-31 |
KR20110089170A (en) | 2011-08-04 |
CN105693701B (en) | 2021-08-10 |
HK1226076A1 (en) | 2017-09-22 |
BRPI0921234A2 (en) | 2016-02-23 |
WO2010054138A2 (en) | 2010-05-14 |
CA2948104C (en) | 2017-09-12 |
UA110192C2 (en) | 2015-12-10 |
RU2014139599A (en) | 2016-04-20 |
CN105693701A (en) | 2016-06-22 |
CA2948104A1 (en) | 2010-05-14 |
ZA201103856B (en) | 2012-02-29 |
SG10201501168RA (en) | 2015-04-29 |
BRPI0921234B8 (en) | 2022-07-19 |
IL212727A (en) | 2014-08-31 |
IL212727A0 (en) | 2011-07-31 |
IL233996A0 (en) | 2014-09-30 |
UA104876C2 (en) | 2014-03-25 |
NZ610972A (en) | 2014-11-28 |
AU2009313409A1 (en) | 2010-05-14 |
JP2012508246A (en) | 2012-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010053471A8 (en) | Modulators of atp-binding cassette transporters | |
WO2010054138A3 (en) | Modulators of atp-binding cassette transporters | |
WO2007117715A3 (en) | Modulators of atp-binding cassette transporters | |
WO2008141119A3 (en) | Modulators of cftr | |
WO2008127399A3 (en) | Azaindole derivatives as cftr modulators | |
WO2009038913A3 (en) | Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis | |
WO2009108657A3 (en) | Heteroaryl derivatives as cftr modulators | |
WO2006099256A3 (en) | Modulators of atp-binding cassette transporters | |
MX357328B (en) | Modulators of atp-binding cassette transporters. | |
HK1148006A1 (en) | Isoquinoline modulators of atp-binding cassette transporters atp | |
AU2010327993A8 (en) | 4-oxo-1H-quinoline-3-carboxamides as modulators of ATP-Binding cassette transporters | |
NZ583878A (en) | Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR) | |
WO2007044560A3 (en) | Modulators of atp-binding cassette transporters | |
WO2006127588A3 (en) | Modulators of atp-binding cassette transporters | |
WO2006002421A3 (en) | Modulators of atp-binding cassette transporters | |
NO20082674L (en) | Heterocyclic modulators for ATP binding cassette transporters | |
WO2005026137A3 (en) | Modulators of atp-binding cassette transporters | |
IL189178A0 (en) | Thiazolyl derivatives and pharmaceutical compositions containing the same | |
WO2010048526A3 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
HK1092353A1 (en) | Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters | |
NZ586271A (en) | Fused pyrimidinone derivatives as modulators of cystic fibrosis transmembrane conductance regulator | |
DE602004022819D1 (en) | TRANSPORTER OF ATP-BINDING CASSETTE | |
EP2502914A3 (en) | Modulators of ATP-binding cassette transporters |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980153970.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09795592 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 592693 Country of ref document: NZ Ref document number: 2009313409 Country of ref document: AU Ref document number: 212727 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011535676 Country of ref document: JP Ref document number: 2742980 Country of ref document: CA Ref document number: MX/A/2011/004834 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2009313409 Country of ref document: AU Date of ref document: 20091106 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2273/KOLNP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20117012767 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2009795592 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009795592 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011122646 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 233996 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: PI0921234 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110505 |